Da Silva Samya Jezine, Cabral-Castro Mauro Jorge, Faria Luiz Claudio, Rosadas Carolina, de Araújo Maria Fernanda Lopes, Dutra Ana Caroline Soares, Yamano Yoshihisa, Taylor Graham, Puccioni-Sohler Marzia
Programa de Pós-Graduação em Doenças Infecciosas e Parasitárias, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.
Departamento de Patologia-Programa de Pós-Graduação em Patologia, Faculdade de Medicina, Universidade Federal Fluminense, Niterói 24070-090, Brazil.
Viruses. 2025 Jan 12;17(1):89. doi: 10.3390/v17010089.
HTLV-1-associated myelopathy (HAM) is a chronic progressive inflammatory disease of the spinal cord. This study assesses the diagnostic accuracy of the neuroinflammatory biomarkers neopterin and cysteine-X-cysteine motif chemokine ligand 10 (CXCL-10) in cerebrospinal fluid (CSF) for HAM.
CSF samples from 75 patients with neurological disorders-33 with HAM (Group A), 19 HTLV-1-seronegative with other neuroinflammatory diseases (Group B), and 23 HTLV-1-seronegative with non-neuroinflammatory diseases (Group C)-were retrospectively evaluated. CSF examination included routine analysis, neopterin, and CXCL-10. The diagnostic potential of the biomarkers was evaluated using receiver operating characteristic curves.
Higher white cell counts and concentrations of protein, neopterin, and CXCL-10 in CSF were detected in group A (patients with HAM) and group B ( < 0.05). Neopterin showed good accuracy for HAM (A) (cut-off 15 nmol/L, 80% sensitivity, 74% specificity) and other neuroinflammation (group B) (cut-off 20 nmol/L, 79% sensitivity, 83% specificity). CXCL-10 demonstrated the highest accuracy in both groups, with Group A (cut-off 110 pg/mL, 97% sensitivity, 96% specificity) and Group B (cut-off 220 pg/mL, 100% sensitivity, 100% specificity).
Neopterin and CXCL-10 in CSF are accurate biomarkers for detecting neuroinflammation, including HAM. CXCL-10, in particular, is the superior biomarker for both chronic and acute neuroinflammatory diseases.
人类嗜T淋巴细胞病毒1型相关脊髓病（HAM）是一种脊髓慢性进行性炎症性疾病。本研究评估脑脊液（CSF）中神经炎症生物标志物新蝶呤和CXC趋化因子配体10（CXCL-10）对HAM的诊断准确性。
回顾性评估了75例神经系统疾病患者的脑脊液样本，其中33例为HAM患者（A组），19例HTLV-1血清学阴性的其他神经炎症性疾病患者（B组），23例HTLV-1血清学阴性的非神经炎症性疾病患者（C组）。脑脊液检查包括常规分析、新蝶呤和CXCL-10检测。使用受试者工作特征曲线评估生物标志物的诊断潜力。
A组（HAM患者）和B组脑脊液中的白细胞计数、蛋白质、新蝶呤和CXCL-10浓度较高（<0.05）。新蝶呤对HAM（A组）显示出良好的准确性（截断值15 nmol/L，灵敏度80%，特异性74%），对其他神经炎症（B组）也有良好准确性（截断值20 nmol/L，灵敏度79%，特异性83%）。CXCL-10在两组中均显示出最高的准确性，A组（截断值110 pg/mL，灵敏度97%，特异性96%），B组（截断值220 pg/mL，灵敏度100%，特异性100%）。
脑脊液中的新蝶呤和CXCL-10是检测包括HAM在内的神经炎症的准确生物标志物。特别是CXCL-10，是慢性和急性神经炎症性疾病的 superior 生物标志物。 （注：原文中“superior”未翻译完整，可能是“更优的”等意思，需结合上下文进一步确定准确含义）
